Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.

Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, King PD, Larson S, Weiss M, Rivière I, Sadelain M.

Nat Med. 2003 Mar;9(3):279-86. Epub 2003 Feb 10.

PMID:
12579196
2.

IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia.

Pegram HJ, Purdon TJ, van Leeuwen DG, Curran KJ, Giralt SA, Barker JN, Brentjens RJ.

Leukemia. 2015 Feb;29(2):415-22. doi: 10.1038/leu.2014.215. Epub 2014 Jul 9.

PMID:
25005243
3.

A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.

Gidlöf C, Dohlsten M, Lando P, Kalland T, Sundström C, Tötterman TH.

Blood. 1997 Mar 15;89(6):2089-97.

4.

In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy.

Lee JC, Hayman E, Pegram HJ, Santos E, Heller G, Sadelain M, Brentjens R.

Cancer Res. 2011 Apr 15;71(8):2871-81. doi: 10.1158/0008-5472.CAN-10-0552. Epub 2011 Apr 12.

5.

Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.

Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, Quintás-Cardama A, Larson SM, Sadelain M.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5426-35. Epub 2007 Sep 12.

6.

Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells.

Cardoso AA, Seamon MJ, Afonso HM, Ghia P, Boussiotis VA, Freeman GJ, Gribben JG, Sallan SE, Nadler LM.

Blood. 1997 Jul 15;90(2):549-61.

7.

Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.

Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C, Yeh R, Capacio V, Olszewska M, Hosey J, Sadelain M, Brentjens RJ, Rivière I.

J Immunother. 2009 Feb-Mar;32(2):169-80. doi: 10.1097/CJI.0b013e318194a6e8.

8.

Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.

Lacerda JF, Ladanyi M, Louie DC, Fernandez JM, Papadopoulos EB, O'Reilly RJ.

J Exp Med. 1996 Mar 1;183(3):1215-28. Erratum in: J Exp Med 1996 Sep 1;184(3):1199.

9.

IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice.

Markley JC, Sadelain M.

Blood. 2010 Apr 29;115(17):3508-19. doi: 10.1182/blood-2009-09-241398. Epub 2010 Feb 26.

10.

Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.

Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL.

J Exp Med. 1991 Jul 1;174(1):139-49.

11.

A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity.

Singh NP, Yolcu ES, Taylor DD, Gercel-Taylor C, Metzinger DS, Dreisbach SK, Shirwan H.

Cancer Res. 2003 Jul 15;63(14):4067-73.

12.

A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease.

Bagnara D, Kaufman MS, Calissano C, Marsilio S, Patten PE, Simone R, Chum P, Yan XJ, Allen SL, Kolitz JE, Baskar S, Rader C, Mellstedt H, Rabbani H, Lee A, Gregersen PK, Rai KR, Chiorazzi N.

Blood. 2011 May 19;117(20):5463-72. doi: 10.1182/blood-2010-12-324210. Epub 2011 Mar 8.

13.

Targeted elimination of prostate cancer by genetically directed human T lymphocytes.

Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC, Brentjens R, Zhong XS, Stephan M, Stefanski J, Lyddane C, Osborne JR, Buchanan IM, Hall SJ, Heston WD, Rivière I, Larson SM, Koutcher JA, Sadelain M.

Cancer Res. 2005 Oct 1;65(19):9080-8.

14.

Primary tumor cells resected from cancer patients and decorated with a novel form of CD80 protein serve as effective antigen-presenting cells for the induction of autologous T cell immune responses ex vivo.

Singh NP, Miller RW, Yolcu ES, Kilinc MO, Oechsli M, Huseby R, Taylor DD, Perry MT, Larocca RV, Shirwan H.

Hum Gene Ther. 2006 Mar;17(3):334-46.

PMID:
16544982
15.

T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells.

Vera J, Savoldo B, Vigouroux S, Biagi E, Pule M, Rossig C, Wu J, Heslop HE, Rooney CM, Brenner MK, Dotti G.

Blood. 2006 Dec 1;108(12):3890-7. Epub 2006 Aug 22.

16.

Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15.

Xu Y, Zhang M, Ramos CA, Durett A, Liu E, Dakhova O, Liu H, Creighton CJ, Gee AP, Heslop HE, Rooney CM, Savoldo B, Dotti G.

Blood. 2014 Jun 12;123(24):3750-9. doi: 10.1182/blood-2014-01-552174. Epub 2014 Apr 29.

17.

Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.

Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, Albelda SM, June CH.

Cancer Res. 2010 Nov 15;70(22):9053-61. doi: 10.1158/0008-5472.CAN-10-2880. Epub 2010 Oct 5.

18.

Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.

Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, Wilson WH, Rosenberg SA.

J Immunother. 2009 Sep;32(7):689-702. doi: 10.1097/CJI.0b013e3181ac6138.

19.

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.

Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, Brentjens RJ.

Blood. 2012 May 3;119(18):4133-41. doi: 10.1182/blood-2011-12-400044. Epub 2012 Feb 21.

20.

Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.

Chekmasova AA, Rao TD, Nikhamin Y, Park KJ, Levine DA, Spriggs DR, Brentjens RJ.

Clin Cancer Res. 2010 Jul 15;16(14):3594-606. doi: 10.1158/1078-0432.CCR-10-0192. Epub 2010 Jul 13.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk